Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

The side effects of the two drugs combined include dizziness, abnormal sensations, altered taste, insomnia, constipation and ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

Zepbound — the brand name for tirzepatide — is the most effective GLP-1 medication for weight loss, according to one study.

Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down.

Injected weight-loss drugs Wegovy, from Novo Nordisk, and Eli Lilly's Zepbound have U.S. list prices of over $1,000 a month.

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

The success of Eli Lilly & Co. 's weight-loss and diabetes drugs has pushed the company's stock to new heights, helping the ...

Novo Nordisk is parting ways with its CEO Lars Fruergaard Jørgensen after the two parties mutually agreed that a change of ...

Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

In today’s Health Alert, two popular weight loss drugs went head-to-head in a clinical trial – and one came out on top.